The discovery of mutations in GC-C and its downstream effector NHE3 in patients with IBD has highlighted impaired intestinal sodium transport as a key player in altering the composition of the gut microbiome, which in turn orchestrates mucosal immune responses. Here, GUCY2C is linked to irritable bowel syndrome.